An update on apocrine lesions of the breast

Histopathology

Volumn 52, Issue 1, 2008, Pages 3-10

  O'Malley, F P ^a,b   Bane, A ^a,b  

^a MOUNT SINAI HOSPITAL   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

Author keywords

Apocrine cysts; Apocrine ductal carcinoma in situ; Breast; cDNA expression arrays; Molecular studies

Indexed keywords

COMPLEMENTARY DNA; EPIDERMAL GROWTH FACTOR RECEPTOR 2;

APOCRINE CARCINOMA; APOCRINE GLAND; BREAST LESION; CANCER INVASION; CARCINOMA IN SITU; COMPARATIVE GENOMIC HYBRIDIZATION; GENE AMPLIFICATION; GENE OVEREXPRESSION; HETEROZYGOSITY LOSS; HUMAN; IMMUNOHISTOCHEMISTRY; MORPHOLOGY; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEOMICS; REVIEW;

APOCRINE GLANDS; BREAST CYST; BREAST NEOPLASMS; CARCINOMA IN SITU; CELL PROLIFERATION; FEMALE; HUMANS; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; RISK FACTORS;

EID: 37249047990     PISSN: 03090167     EISSN: 13652559     Source Type: Journal    
DOI: 10.1111/j.1365-2559.2007.02888.x     Document Type: Review

References (61)

1. Devitt JE, To T, Miller AB. Risk of breast cancer in women with breast cysts. CMAJ 1992 147 45 49.
2. Jones BM, Bradbeer JW. The presentation and progress of macroscopic breast cysts. Br. J. Surg. 1980 67 669 671.
3. Haagensen CD, Bodian CA, Haagensen DE Jr. Breast cancer risk and detection. Philadelphia : W. B. Saunders, 1981.
4. Roberts MM, Jones V, Elton RA, Fortt RW, Williams S, Gravelle IH. Risk of breast cancer in women with history of benign disease of the breast. Br. Med. J. (Clin. Res. Ed.) 1984 288 275 278.
5. Bundred NJ, West RR, Dowd JO, Mansel RE, Hughes LE. Is there an increased risk of breast cancer in women who have had a breast cyst aspirated? Br. J. Cancer 1991 64 953 955.
6. Bruzzi P, Dogliotti L, Naldoni C et al. Cohort study of association of risk of breast cancer with cyst type in women with gross cystic disease of the breast. BMJ 1997 314 925 928.
7. Dixon JM, McDonald C, Miller WR. Risk of breast cancer in women with palpable breast cysts: a prospective study. Lancet 1999 353 1742 1745.
8. Dupont WD, Page DL. Risk factors for breast cancer in women with proliferative breast disease. N. Engl. J. Med. 1985 312 146 151.
9. Fitzgibbons PL, Henson DE, Hutter RV. Benign breast changes and the risk for subsequent breast cancer: an update of the 1985 consensus statement. Cancer Committee of the College of American Pathologists. Arch. Pathol. Lab. Med. 1998 122 1053 1055.
10. Page DL, Dupont WD, Jensen RA. Papillary apocrine change of the breast: associations with atypical hyperplasia and risk of breast cancer. Cancer Epidemiol. Biomarkers Prev. 1996 5 29 32.
11. Eusebi V, Casadei GP, Bussolati G, Azzopardi JG. Adenomyoepithelioma of the breast with a distinctive type of apocrine adenosis. Histopathology 1987 11 305 315.
12. Simpson JF, Page DL, Dupont WD. Apocrine adenosis - a mimic of mammary carcinoma. Surg. Pathol. 1990 3 289 299.
13. Carter DJ, Rosen PP. Atypical apocrine metaplasia in sclerosing lesions of the breast: a study of 51 patients. Mod. Pathol. 1991 4 1 5.
14. Seidman JD, Ashton M, Lefkowitz M. Atypical apocrine adenosis of the breast: a clinicopathologic study of 37 patients with 8.7-year follow-up. Cancer 1996 77 2529 2537.
15. Endoh Y, Tamura G, Kato N, Motoyama T. Apocrine adenosis of the breast: clonal evidence of neoplasia. Histopathology 2001 38 221 224.
16. Wells CA, McGregor IL, Makunura CN, Yeomans P, Davies JD. Apocrine adenosis: a precursor of aggressive breast cancer? J. Clin. Pathol. 1995 48 737 742.
17. Selim AG, Wells CA. Immunohistochemical localisation of androgen receptor in apocrine metaplasia and apocrine adenosis of the breast: relation to oestrogen and progesterone receptors. J. Clin. Pathol. 1999 52 838 841.
18. Moriya T, Sakamoto K, Sasano H et al. Immunohistochemical analysis of Ki-67, p53, p21, and p27 in benign and malignant apocrine lesions of the breast: its correlation to histologic findings in 43 cases. Mod. Pathol. 2000 13 13 18.
19. Eusebi V, Damiani S, Losi L, Millis RR. Apocrine differentiation in breast epithelium. Adv. Anat. Pathol. 1997 4 139 155.
20. Page DL, Rogers LW. Combined histologic and cytologic criteria for the diagnosis of mammary atypical ductal hyperplasia. Hum. Pathol. 1992 23 1095 1097.
21. O'Malley FP, Bane AL. The spectrum of apocrine lesions of the breast. Adv. Anat. Pathol. 2004 11 1 9.
22. O'Malley FP, Page DL, Nelson EH, Dupont WD. Ductal carcinoma in situ of the breast with apocrine cytology: definition of a borderline category. Hum. Pathol. 1994 25 164 168.
23. Tavassoli FA, Norris HJ. Intraductal apocrine carcinoma: a clinicopathologic study of 37 cases. Mod. Pathol. 1994 7 813 818.
24. Scott MA, Lagios MD, Axelsson K, Rogers LW, Anderson TJ, Page DL. Ductal carcinoma in situ of the breast: reproducibility of histological subtype analysis. Hum. Pathol. 1997 28 967 973.
25. Leal C, Henrique R, Monteiro P et al. Apocrine ductal carcinoma in situ of the breast: histologic classification and expression of biologic markers. Hum. Pathol. 2001 32 487 493.
26. Mossler JA, Barton TK, Brinkhous AD, McCarty KS, Moylan JA, McCarty KSJ. Apocrine differentiation in human mammary carcinoma. Cancer 1980 46 2463 2471.
27. Abati AD, Kimmel M, Rosen PP. Apocrine mammary carcinoma. A clinicopathologic study of 72 cases. Am. J. Clin. Pathol. 1990 94 371 377.
28. d'Amore ES, Terrier-Lacombe MJ, Travagli JP, Friedman S, Contesso G. Invasive apocrine carcinoma of the breast: a long term follow-up study of 34 cases. Breast Cancer Res. Treat. 1988 12 37 44.
29. Japaze H, Emina J, Diaz C et al. 'Pure' invasive apocrine carcinoma of the breast: a new clinicopathological entity? Breast 2005 14 3 10.
30. Azzopardi JG. Problems in breast pathology. Philadelphia : W.B. Saunders, 1979.
31. Frable WJ, Kay S. Carcinoma of the breast. Histologic and clinical features of apocrine tumors. Cancer 1968 21 756 763.
32. Eusebi V, Millis RR, Cattani MG, Bussolati G, Azzopardi JG. Apocrine carcinoma of the breast. A morphologic and immunocytochemical study. Am. J. Pathol. 1986 123 532 541.
33. Rosen PP. Rosen's breast pathology, 2nd edn. Philadelphia, PA : Lippincott Williams & Wilkins, 2001.
34. Haagensen CD. Diseases of the breast, 3rd edn. Philadelphia : W.B. Saunders, 1986.
35. Eusebi V, Magalhaes F, Azzopardi JG. Pleomorphic lobular carcinoma of the breast: an aggressive tumor showing apocrine differentiation. Hum. Pathol. 1992 23 655 662.
36. Mazoujian G, Pinkus GS, Davis S, Haagensen DE Jr. Immunohistochemistry of a gross cystic disease fluid protein (GCDFP-15) of the breast. A marker of apocrine epithelium and breast carcinomas with apocrine features. Am. J. Pathol. 1983 110 105 112.
37. Miller WR, Shivas AA, Franchimont P, Haagensen DE. Breast gross cystic disease protein 15 in human breast cancer in culture. Eur. J. Cancer Clin. Oncol. 1988 24 223 228.
38. Shoker BS, Jarvis C, Clarke RB et al. Abnormal regulation of the oestrogen receptor in benign breast lesions. J. Clin. Pathol. 2000 53 778 783.
39. Gatalica Z. Immunohistochemical analysis of apocrine breast lesions. Consistent over-expression of androgen receptor accompanied by the loss of estrogen and progesterone receptors in apocrine metaplasia and apocrine carcinoma in situ. Pathol. Res. Pract. 1997 193 753 758.
40. Tran DD, Lawson JS. Microcysts and breast cancer: a study of biological markers in archival biopsy material. Breast Cancer Res. Treat. 2002 75 213 220.
41. Honma N, Takubo K, Akiyama F et al. Expression of GCDFP-15 and AR decreases in larger or node-positive apocrine carcinomas of the breast. Histopathology 2005 47 195 201.
42. Moinfar F, Okcu M, Tsybrovskyy O et al. Androgen receptors frequently are expressed in breast carcinomas: potential relevance to new therapeutic strategies. Cancer 2003 98 703 711.
43. Castiglione F, Sarotto I, Fontana V et al. Bcl2, p53 and clinical outcome in a series of 138 operable breast cancer patients. Anticancer Res. 1999 19 4555 4563.
44. Kroger N, Milde-Langosch K, Riethdorf S et al. Prognostic and predictive effects of immunohistochemical factors in high-risk primary breast cancer patients. Clin. Cancer Res. 2006 12 159 168.
45. Leek RD, Kaklamanis L, Pezzella F, Gatter KC, Harris AL. Bcl-2 in normal human breast and carcinoma, association with oestrogen receptor-positive, epidermal growth factor receptor-negative tumours and in situ cancer. Br. J. Cancer 1994 69 135 139.
46. Selim AG, El-Ayat G, Wells CA. Expression of c-erbB2, p53, Bcl-2, Bax, c-myc and Ki-67 in apocrine metaplasia and apocrine change within sclerosing adenosis of the breast. Virchows Arch. 2002 441 449 455.
47. Agnantis NJ, Mahera H, Maounis N, Spandidos DA. Immunohistochemical study of ras and myc oncoproteins in apocrine breast lesions with and without papillomatosis. Eur. J. Gynaecol. Oncol. 1992 13 309 315.
48. Selim AG, El-Ayat G, Naase M, Wells CA. C-myc oncoprotein expression and gene amplification in apocrine metaplasia and apocrine change within sclerosing adenosis of the breast. Breast 2002 11 466 472.
49. Maitra A, Wistuba IL II., Washington C et al. High-resolution chromosome 3p allelotyping of breast carcinomas and precursor lesions demonstrates frequent loss of heterozygosity and a discontinuous pattern of allele loss. Am. J. Pathol. 2001 159 119 130.
50. Selim AG, Ryan A, El-Ayat G, Wells CA. Loss of heterozygosity and allelic imbalance in apocrine metaplasia of the breast: microdissection microsatellite analysis. J. Pathol. 2002 196 287 291.
51. Washington C, Dalbegue F, Abreo F, Taubenberger JK, Lichy JH. Loss of heterozygosity in fibrocystic change of the breast: genetic relationship between benign proliferative lesions and associated carcinomas. Am. J. Pathol. 2000 157 323 329.
52. Jones C, Damiani S, Wells D, Chaggar R, Lakhani SR, Eusebi V. Molecular cytogenetic comparison of apocrine hyperplasia and apocrine carcinoma of the breast. Am. J. Pathol. 2001 158 207 214.
53. Perou CM, Sorlie T, Eisen MB et al. Molecular portraits of human breast tumours. Nature 2000 406 747 752.
54. Sorlie T, Perou CM, Tibshirani R et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc. Natl. Acad. Sci. U.S.A. 2001 98 10869 10874.
55. Sorlie T, Tibshirani R, Parker J et al. Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc. Natl. Acad. Sci. U.S.A. 2003 100 8418 8423.
56. Fan C, Oh DS, Wessels L et al. Concordance among gene-expression-based predictors for breast cancer. N. Engl. J. Med. 2006 355 560 569.
57. Simpson PT, Reis-Filho JS, Gale T, Lakhani SR. Molecular evolution of breast cancer. J. Pathol. 2005 205 248 254.
58. Sotiriou C, Neo SY, McShane LM et al. Breast cancer classification and prognosis based on gene expression profiles from a population-based study. Proc. Natl. Acad. Sci. U.S.A. 2003 100 10393 10398.
59. Farmer P, Bonnefoi H, Becette V et al. Identification of molecular apocrine breast tumours by microarray analysis. Oncogene 2005 24 4660 4671.
60. Celis JE, Gromov P, Moreira JM et al. Apocrine cysts of the breast: biomarkers, origin, enlargement, and relation with cancer phenotype. Mol. Cell Proteomics 2006 5 462 483.
61. Celis JE, Gromova I, Gromov P et al. Molecular pathology of breast apocrine carcinomas: a protein expression signature specific for benign apocrine metaplasia. FEBS Lett. 2006 580 2935 2944.